First LockeT Cases Completed in Germany
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT cases in Germany at Zentralklinik Bad Berka, one of Thuringia's largest hospitals.
The medical team has successfully conducted 10 cases using LockeT to close single or multiple punctures with a single device per case. The procedures demonstrated LockeT's versatility by handling sheath sizes ranging from 6F to 17Fr. The company views Germany as a significant European market opportunity, particularly due to its price-conscious nature.
Catheter Precision (NYSE:VTAK), azienda statunitense di dispositivi medici, ha annunciato il completamento con successo dei suoi primi casi LockeT in Germania presso la Zentralklinik Bad Berka, uno dei maggiori ospedali della Turingia.
Il team medico ha eseguito con successo 10 casi utilizzando LockeT per chiudere una o più punture con un unico dispositivo per intervento. Le procedure hanno dimostrato la versatilità di LockeT gestendo calibri di guaina compresi tra 6F e 17Fr. L'azienda considera la Germania un'importante opportunità di mercato in Europa, soprattutto per la sua attenzione al prezzo.
Catheter Precision (NYSE:VTAK), una compañía estadounidense de dispositivos médicos, ha anunciado la finalización con éxito de sus primeros casos LockeT en Alemania en la Zentralklinik Bad Berka, uno de los mayores hospitales de Turingia.
El equipo médico realizó con éxito 10 casos utilizando LockeT para cerrar punciones simples o múltiples con un único dispositivo por caso. Los procedimientos demostraron la versatilidad de LockeT al manejar tamaños de vaina desde 6F hasta 17Fr. La empresa considera a Alemania una oportunidad de mercado europea significativa, en particular por su sensibilidad al precio.
Catheter Precision (NYSE:VTAK)는 미국에 본사를 둔 의료기기 회사로서 튀링겐의 주요 병원 중 하나인 Zentralklinik Bad Berka에서 자사의 첫 LockeT 시술(독일)을 성공적으로 완료했다고 발표했습니다.
의료진은 10건의 시술을 성공적으로 수행했으며, 각 사례당 하나의 기기로 단일 또는 다중 천공을 폐쇄했습니다. 이들 시술은 LockeT가 6F에서 17Fr 범위의 쉘 크기를 처리할 수 있음을 보여주며 유연성을 입증했습니다. 회사는 독일을 가격 민감성이 높은 중요한 유럽 시장 기회로 보고 있습니다.
Catheter Precision (NYSE:VTAK), une entreprise américaine de dispositifs médicaux, a annoncé l'achèvement avec succès de ses premiers cas LockeT en Allemagne à la Zentralklinik Bad Berka, l'un des plus grands hôpitaux de Thuringe.
L'équipe médicale a mené à bien 10 cas en utilisant LockeT pour fermer des ponctions simples ou multiples avec un seul dispositif par cas. Les procédures ont démontré la polyvalence de LockeT, prenant en charge des gaines de tailles allant de 6F à 17Fr. La société considère l'Allemagne comme une opportunité de marché européenne majeure, notamment en raison de sa sensibilité au prix.
Catheter Precision (NYSE:VTAK), ein US-amerikanisches Medizintechnikunternehmen, hat den erfolgreichen Abschluss seiner ersten LockeT-Fälle in Deutschland in der Zentralklinik Bad Berka bekannt gegeben, einem der größten Krankenhäuser Thüringens.
Das medizinische Team führte erfolgreich 10 Fälle durch und setzte LockeT ein, um einzelne oder mehrere Punktionen jeweils mit nur einem Gerät zu verschließen. Die Eingriffe zeigten die Vielseitigkeit von LockeT beim Umgang mit Schaftgrößen von 6F bis 17Fr. Das Unternehmen sieht in Deutschland eine bedeutende Chance auf dem europäischen Markt, insbesondere wegen seiner Preisbewusstheit.
- Successfully completed first 10 LockeT cases in Germany
- Device demonstrated versatility across multiple sheath sizes (6F to 17Fr)
- Entry into Germany, one of Europe's largest markets
- None.
FORT MILL, S.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the first LockeT cases were recently completed in Germany at Zentralklinik Bad Berka. With a total of 20 clinics and specialist departments, it is one of the largest hospitals in Thuringia.
To date, the physician team has successfully performed 10 cases, using LockeT to close single or multiple punctures with just one device per case. These procedures have spanned sheath sizes from 6F to 17Fr, demonstrating LockeT’s versatility and reliability.
David Jenkins, CEO of Catheter Precision said, “Germany is one of the largest markets in Europe and price conscious, making LockeT a great solution. As we continue our partnership with Bad Berka, we also look forward to expanding our footprint to other centers in Germany. We extend our sincere thanks to Professor J. Christoph Geller, Dr. Santi Raffa, Dr. Markus Frommhold, who is also the very first user of LockeT in Germany, and Dr. Obaida Alothman for their invaluable support and feedback.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What is the recent announcement from Catheter Precision (VTAK) regarding LockeT in Germany?
How many LockeT procedures has Catheter Precision (VTAK) completed at Zentralklinik Bad Berka?
What range of sheath sizes can Catheter Precision's (VTAK) LockeT device accommodate?
Which German hospital performed the first LockeT procedures for Catheter Precision (VTAK)?
